Uncommon Cents Investing LLC Raises Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Uncommon Cents Investing LLC boosted its holdings in Bristol-Myers Squibb (NYSE:BMY) by 69.7% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 9,045 shares of the biopharmaceutical company’s stock after buying an additional 3,715 shares during the period. Uncommon Cents Investing LLC’s holdings in Bristol-Myers Squibb were worth $464,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of BMY. Austin Private Wealth LLC boosted its holdings in shares of Bristol-Myers Squibb by 27.2% during the 4th quarter. Austin Private Wealth LLC now owns 4,643 shares of the biopharmaceutical company’s stock valued at $238,000 after purchasing an additional 994 shares during the last quarter. Ritholtz Wealth Management boosted its holdings in shares of Bristol-Myers Squibb by 4.8% during the 4th quarter. Ritholtz Wealth Management now owns 15,665 shares of the biopharmaceutical company’s stock valued at $804,000 after purchasing an additional 720 shares during the last quarter. Accel Wealth Management boosted its holdings in shares of Bristol-Myers Squibb by 12.7% during the 4th quarter. Accel Wealth Management now owns 4,146 shares of the biopharmaceutical company’s stock valued at $213,000 after purchasing an additional 467 shares during the last quarter. WASHINGTON TRUST Co boosted its holdings in shares of Bristol-Myers Squibb by 6.1% during the 4th quarter. WASHINGTON TRUST Co now owns 15,460 shares of the biopharmaceutical company’s stock valued at $793,000 after purchasing an additional 894 shares during the last quarter. Finally, Next Level Private LLC boosted its holdings in shares of Bristol-Myers Squibb by 8.2% during the 4th quarter. Next Level Private LLC now owns 58,223 shares of the biopharmaceutical company’s stock valued at $2,987,000 after purchasing an additional 4,412 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on BMY shares. StockNews.com raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Friday, March 1st. Societe Generale downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Bank of America downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price target for the company from $68.00 to $60.00 in a report on Wednesday, January 3rd. Redburn Atlantic downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price target for the company from $77.00 to $54.00 in a report on Tuesday, February 6th. Finally, Wells Fargo & Company reduced their price objective on shares of Bristol-Myers Squibb from $58.00 to $51.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 6th. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $61.12.

Bristol-Myers Squibb Stock Up 1.8 %

BMY stock traded up $0.98 during trading on Thursday, hitting $54.23. 14,346,012 shares of the company’s stock traded hands, compared to its average volume of 16,860,898. The firm has a market capitalization of $109.91 billion, a P/E ratio of 14.08, a PEG ratio of 1.59 and a beta of 0.38. The business has a fifty day simple moving average of $50.79 and a two-hundred day simple moving average of $52.44. The company has a quick ratio of 1.31, a current ratio of 1.43 and a debt-to-equity ratio of 1.24. Bristol-Myers Squibb has a 1 year low of $47.58 and a 1 year high of $71.07.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.55 by $0.15. The company had revenue of $11.48 billion for the quarter, compared to analyst estimates of $11.19 billion. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. Bristol-Myers Squibb’s revenue was up .6% compared to the same quarter last year. During the same period last year, the company posted $1.82 earnings per share. Sell-side analysts anticipate that Bristol-Myers Squibb will post 6.61 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 4.43%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is 62.18%.

Bristol-Myers Squibb declared that its Board of Directors has initiated a stock buyback plan on Thursday, December 7th that allows the company to buyback $3.00 billion in outstanding shares. This buyback authorization allows the biopharmaceutical company to purchase up to 2.9% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.